Compounded Semaglutide Dosing and Protocols: A Complete Clinical Reference

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Semaglutide dosing is the single most misunderstood part of GLP-1 therapy. Patients arrive at consultations with screenshots of doses from Reddit threads, photos of pharmacy vials with milligram labels they cannot interpret, and questions about why their friend on a different protocol seems to be at a higher dose at the same week of therapy. This page exists to answer those questions in one place, using the published clinical trial data that established the dosing framework, and to explain how compounded semaglutide protocols relate to that framework.

Compounded semaglutide is not FDA-approved. Dosing for compounded preparations is determined by the prescribing clinician based on patient-specific factors and is informed by, but not identical to, the titration schedule used in the trials that supported approval of Wegovy and Ozempic. The doses cited in this guide reference the published Wegovy escalation schedule, the Ozempic escalation schedule, and the dose-response data from SUSTAIN, STEP-1, STEP-3, and STEP-4. This is a reference document, not a prescription, and it should not be used to self-titrate.

For context on what compounded semaglutide is, how 503A and 503B pharmacies prepare it, and the legal framework that governs its dispensing, see the pillar guide on compounded semaglutide.

The Standard Wegovy Titration Schedule

The FDA-approved Wegovy titration schedule is the reference point against which most compounded semaglutide protocols are written. It was designed to allow the gastrointestinal system to adapt slowly, which is the single most important factor in tolerability.

The schedule is five steps over sixteen weeks:

Weeks 1 through 4: 0.25 mg once weekly
Weeks 5 through 8: 0.5 mg once weekly
Weeks 9 through 12: 1.0 mg once weekly
Weeks 13 through 16: 1.7 mg once weekly
Week 17 onward: 2.4 mg once weekly (maintenance)

The full clinical effect on weight is not achieved at the starting dose. The 2.4 mg maintenance dose was the dose tested in STEP-1, the trial that established Wegovy's labeled indication for chronic weight management, and it was the dose at which patients lost a mean of 14.9 percent of body weight over 68 weeks compared to 2.4 percent on placebo.

The 0.25 mg starting dose is not a therapeutic dose. It is a tolerability dose. It exists to let the slow gastric emptying effect that drives most GI side effects develop gradually rather than all at once.

The Ozempic Titration Schedule

Ozempic, approved for type 2 diabetes rather than weight management, uses a different escalation path and tops out at a lower maintenance dose:

Weeks 1 through 4: 0.25 mg once weekly
Weeks 5 through 8: 0.5 mg once weekly
Week 9 onward: 1.0 mg once weekly, with possible escalation to 2.0 mg

The Ozempic maintenance dose for glycemic control is 0.5 mg or 1.0 mg. A 2.0 mg dose was added to the label after the SUSTAIN-FORTE trial demonstrated additional A1c reduction. Ozempic was not designed to push to the 2.4 mg dose used in weight management trials, which is why patients seeking weight loss outcomes who are prescribed Ozempic off-label often find their results plateau earlier than expected.

How Compounded Semaglutide Protocols Are Written

Compounded semaglutide is dispensed by a 503A pharmacy or a 503B outsourcing facility under an individual prescription. The prescribing clinician sets the dose, the titration interval, and the concentration of the preparation. There is no single standardized compounded protocol because compounded preparations are, by definition, patient-specific.

Most clinically reasonable compounded protocols follow the published Wegovy escalation curve closely. A typical structure is the same five-step titration over sixteen weeks, with the prescribing clinician retaining discretion to pause or extend any step if the patient is experiencing side effects, has lost an adequate amount of weight at a lower dose, or has clinical reasons to escalate more slowly.

Some clinicians use a slightly slower titration than the Wegovy schedule, for example holding each step for five or six weeks rather than four, in patients who have a history of GI sensitivity, gastroparesis risk factors, or who are starting from a lower baseline BMI. Slower titration tends to produce better adherence because GI side effects are the leading cause of GLP-1 discontinuation in the published literature.

For a deeper dive into how 503A and 503B compounding works, see our supporting article on 503A versus 503B pharmacies.

Units, Milligrams, and the Confusion That Causes Dosing Errors

The single most common patient error with compounded semaglutide is confusing milligrams with units on an insulin syringe. This error has caused hospitalizations.

Semaglutide is dosed in milligrams. Insulin syringes are calibrated in units, where 1 unit equals 0.01 mL on a standard U-100 syringe. The milligram dose corresponds to a different number of units depending on the concentration of the vial the pharmacy dispenses.

A 2.5 mg/mL preparation and a 5 mg/mL preparation will require different syringe volumes to deliver the same milligram dose. The correct number of units for a given dose is determined by the pharmacy and should appear on the prescription label and dosing instructions. Patients should never calculate their own dose from a Reddit chart or from a friend's vial. Concentrations vary between pharmacies and even between batches.

If your vial label and your dosing instructions do not match, do not inject. Call your prescribing clinic.

Skipped Doses and Restart Protocols

The Wegovy and Ozempic prescribing information includes specific guidance for missed doses, and most compounded protocols mirror this guidance.

If a dose is missed and the next scheduled dose is more than 48 hours away, the missed dose can be administered as soon as it is remembered. If the next scheduled dose is less than 48 hours away, the missed dose should be skipped and the next scheduled dose taken at the regular time. Doses should not be doubled to make up for a missed dose.

If two or more consecutive doses are missed, the Wegovy label recommends restarting at the most recent tolerated dose for one cycle before resuming titration, and the same logic applies to many compounded protocols. A patient who was at 1.7 mg and missed three weeks of doses would typically restart at 1.0 mg for four weeks before stepping back up. The reason is that the slow gastric emptying effect that produces tolerability declines within days of stopping the drug, and a full-dose restart in a patient who has lost tolerance is the leading cause of severe nausea and emergency department visits.

For more on this, see our article on restarting semaglutide after a break.

Dose Holds and Side Effect Management

A dose hold is a clinical decision to keep a patient at their current dose for an additional cycle rather than escalating on the scheduled week. Dose holds are appropriate when:

The patient is experiencing persistent moderate to severe nausea, vomiting, or diarrhea
The patient has lost an adequate amount of weight on the current dose and does not need additional appetite suppression
The patient is approaching a goal weight and the clinician is preparing for maintenance
The patient has had a recent change in concurrent medications or medical condition that warrants stability

Dose reductions, where the clinician steps the patient back down to a previous dose, are used when side effects are intolerable but the patient and clinician want to continue therapy. The published trials show that approximately 7 percent of Wegovy patients discontinued due to GI adverse events, and the most common alternative to discontinuation in clinical practice is a dose reduction with extended titration.

For a complete breakdown of the side effect profile, see our cluster hub on semaglutide side effects and safety.

What the Trials Showed at Each Dose

The dose-response relationship for semaglutide weight loss is well characterized. STEP-1 reported that at 2.4 mg, mean weight loss was 14.9 percent over 68 weeks. STEP-3, which combined 2.4 mg semaglutide with intensive behavioral therapy, reported 16.0 percent. STEP-4, which examined dose continuation versus withdrawal, showed that patients who continued 2.4 mg for an additional 48 weeks lost an additional 7.9 percent of body weight, while patients switched to placebo regained 6.9 percent.

At lower doses, weight loss is proportionally lower. SUSTAIN trials in type 2 diabetes patients showed weight loss in the range of 4 to 6 percent at the 1.0 mg dose. Patients on compounded semaglutide protocols that target the lower diabetes-style doses should not expect the same weight outcomes as patients on the full 2.4 mg weight-management dose.

This is one of the most important conversations to have with a prescribing clinician. The dose you are prescribed determines the result you can reasonably expect. There is no shortcut. Higher doses are not better for everyone, and many patients achieve excellent outcomes at 1.7 mg without ever needing to push to 2.4 mg, but lower doses cannot be expected to produce upper-dose results.

Maintenance Dosing After Reaching Goal Weight

Maintenance dosing is the dose a patient takes after reaching their goal weight or after the active weight-loss phase of therapy ends. The published evidence on maintenance dosing comes primarily from STEP-4, which compared continuation of 2.4 mg to placebo after a 20-week run-in.

Most clinically reasonable maintenance protocols hold the patient at the dose at which they achieved their goal weight. If a patient reached goal at 1.7 mg, the maintenance dose is typically 1.7 mg. If they reached goal at 2.4 mg, the maintenance dose is typically 2.4 mg, though some clinicians step down to 1.7 mg after a period of weight stability.

Lower-dose maintenance, such as 0.5 mg or 1.0 mg every other week, is sometimes used in patients who want to minimize cost and side effects after reaching goal. This is an off-label approach, the evidence base is limited, and it should be discussed with the prescribing clinician on a case-by-case basis. The risk of lower-dose maintenance is weight regain, which the STEP-4 data suggest is biologically driven and not a function of willpower.

For more on maintenance, see our cluster hub on long-term and maintenance.

Injection Technique and Site Rotation

Semaglutide is administered as a subcutaneous injection once weekly. Approved injection sites are the abdomen (avoiding a two-inch radius around the navel), the front of the thigh, and the back of the upper arm. The injection should be subcutaneous, not intramuscular, and should be rotated between sites to reduce the risk of lipohypertrophy and injection-site reactions.

The injection should be given on the same day of the week, but the time of day does not matter. Semaglutide has a half-life of approximately one week, so the timing within the day is clinically irrelevant. It can be taken with or without food.

Vials should be stored refrigerated between 36 and 46 degrees Fahrenheit. Once a vial is in use, most compounded preparations are stable at room temperature for up to 28 days, but specific stability windows depend on the pharmacy's beyond-use date, which should be on the label. Do not use a vial past its beyond-use date.

For step-by-step injection technique, see our article on how to inject compounded semaglutide.

Special Populations and Dose Adjustment

The Wegovy label does not require dose adjustment for renal impairment, hepatic impairment, or age in the populations studied, but caution and slower titration are recommended in patients with severe renal disease, end-stage liver disease, or a history of pancreatitis. Compounded semaglutide protocols typically follow the same caution framework.

Patients on insulin or sulfonylureas who are taking semaglutide for glycemic control or for combined glycemic and weight indications are at increased risk of hypoglycemia. Dose adjustment of the concurrent diabetes medication, not of the semaglutide, is the standard approach. This requires coordination with the patient's primary diabetes care team.

Pregnancy and breastfeeding are contraindications. Semaglutide should be discontinued at least two months before a planned pregnancy due to its long half-life. Patients of childbearing potential should use reliable contraception during therapy.

This hub is part of the Compounded Semaglutide Dosing and Protocols cluster. Related supporting articles include:

For the foundational overview of compounded semaglutide, return to the pillar guide.

Not FDA-approved. HealthRX is not a medical practice. Information on this site is for educational purposes and is not a substitute for individualized medical advice. Treatment decisions are made between you and a licensed clinician. Compounded semaglutide is dispensed by state-licensed 503A pharmacies and FDA-registered 503B outsourcing facilities under individual prescriptions. References: SUSTAIN program (Sorli et al., Lancet Diabetes Endocrinol 2017; Ahrén et al., Lancet Diabetes Endocrinol 2017), STEP-1 (Wilding et al., NEJM 2021), STEP-3 (Wadden et al., JAMA 2021), STEP-4 (Rubino et al., JAMA 2021), SELECT (Lincoff et al., NEJM 2023).

This HealthRX guide is educational and is not a prescription, diagnosis, or substitute for care from a licensed clinician. Compounded semaglutide is not FDA-approved. Treatment decisions should be made with a prescriber who has reviewed your medical history.